Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain

 Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain

Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain

Shots:

  • The company to initiate the clinical trial assessing the safety and efficacy of its COVID-19 drug based on the Grifols’ immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal Abs from plasma donors who have recovered from the disease
  • The study is expected to be initiated in Feb’2021. The treatment will be administered in primary care centers in people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination
  • The Grifols immunoglobulin Gamunex-C (IV, IM, SC) has proven to be safe and efficacious in the prevention of diverse infectious diseases in an immunocompromised patient

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Yicai Global

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post